This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alkermes' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

So we have a number of drugs now in development, two which are very important stage for investors to understand. One is the drug called ALKS 9070. ALKS 9070 is our own long-acting injectable for the treatment of schizophrenia. In this case it’s a long-acting pro-drug of aripiprazole.

This will build up the foundation. It’s been build with RISPERDAL CONSTA and INVEGA SUSTENNA, two of our biggest commercial products already sold by Johnson & Johnson.

So we’ve come to understand the long-acting atypical antipsychotic market. It’s a big market. It’s a $2 billion franchise and growing double digits. Its still underserved in terms of the medical necessity for these products and ALKS 9070 fills a very clear niche in that market, which is a desire for long-acting form of one of the better tolerated antipsychotic.

And ABILIFY is that type of drug. It’s a $4 billion drug. We are developing the long-acting injectable in Phase 3. We should have results from that Phase 3 clinical trial next year and those data will be sufficient to file for FDA approval in United States.

So 9070 is Phase 3 asset. It’s right in our power alley in schizophrenia long-acting medications and we are quite excited about it. Has a major effect in our models on evaluation if that drug is successful.

Second drug I’ll mention then we can talk where we want to take is 5461. 5461 is a drug that you have to say is more risky at this moment, because its based on only one efficacy study so far.

And that’s a drug for the treatment of depression, but particularly treatment-resistant depression for patients who have failed treatment with SSRI and conventional any depression medication.

This is based on our deep understanding of opioid receptor biology, which is good in our chemistry capability and opioid receptor modulators, as well as our clinical experience with opioid receptor modulation through VIVITROL and other work.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs